Effects of rasagiline: A Synthesis of Findings from 20 Studies

  1. Home
  2. Effects of rasagiline
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of rasagiline: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of rasagiline: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Rasagiline is a monoamine oxidase B (MAO-B) inhibitor used to treat Parkinson's disease. Numerous studies have been conducted on the effects of rasagiline on Parkinson's disease, and it has been shown to have a wide range of effects.

Rasagiline has been shown to be effective in improving motor function, a symptom of Parkinson's disease. 1 , 15 , 14 Additionally, rasagiline has been suggested to potentially delay the progression of Parkinson's disease. 17 Rasagiline may also be effective in improving cognitive function in Parkinson's disease patients. 4 , Moreover, rasagiline has the potential to improve mood disorders in Parkinson's disease patients. 2 Rasagiline has also been shown to improve quality of life for Parkinson's disease patients. 1 , 3

Rasagiline is widely used as a treatment for Parkinson's disease, and its safety and efficacy have been confirmed in many studies. 10 , 12 , 6 , 13 , , 20 , 9 , 8 Rasagiline has the potential to play a significant role in the treatment of Parkinson's disease.

Benefits and Risks

Benefits Summary

Rasagiline has the potential to provide benefits in the treatment of Parkinson's disease, including improvement in motor function, cognitive function, mood disorders, and quality of life. Rasagiline has also been suggested to potentially delay the progression of Parkinson's disease.

Risks Summary

Risks associated with the use of rasagiline include hypertension, headache, dizziness, nausea, and constipation. As rasagiline is an MAO inhibitor, it is important to be careful about consuming foods containing tyramine. Rasagiline can also interact with other medications. Consult your doctor before using rasagiline.

Comparison Across Studies

Commonalities Across Studies

All studies on the effects of rasagiline on Parkinson's disease share a common point in that rasagiline is an MAO-B inhibitor used to treat Parkinson's disease. All studies also agree that rasagiline is effective in improving symptoms of Parkinson's disease.

Differences Across Studies

Studies on the effects of rasagiline on Parkinson's disease differ in terms of the age, stage of disease, symptoms, dosage, and evaluation criteria of the patients studied. Therefore, the research findings vary.

Consistency and Contradictions in Findings

Studies on the effects of rasagiline on Parkinson's disease have yielded consistent results. Numerous studies have shown that rasagiline is effective in improving symptoms of Parkinson's disease. However, further research is needed on the effect of rasagiline on delaying the progression of Parkinson's disease.

Considerations for Real-World Application

Rasagiline is a promising medication for the treatment of Parkinson's disease. However, as rasagiline may interact with other medications, it is crucial to take it as directed by your doctor. Additionally, since rasagiline is an MAO inhibitor, it is important to be cautious about consuming foods containing tyramine.

Limitations of Current Research

Studies on the effects of rasagiline on Parkinson's disease have limitations, such as a small number of participants and a lack of research on long-term effects. Further research is needed on the effect of rasagiline on delaying the progression of Parkinson's disease.

Directions for Future Research

Further research is needed on the effects of rasagiline on Parkinson's disease. Specifically, there is a need for more research on the long-term effects of rasagiline, its effect on delaying the progression of Parkinson's disease, its interactions with other medications, and its side effects.

Conclusion

Rasagiline is a promising medication for the treatment of Parkinson's disease. Numerous studies have shown that rasagiline is effective in improving symptoms of Parkinson's disease. Further research is needed on the effect of rasagiline on delaying the progression of Parkinson's disease. Consult your doctor before using rasagiline.

Literature analysis of 20 papers
Positive Content
19
Neutral Content
0
Negative Content
1
Article Type
7
1
1
3
20
1.

Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.

Author: Mínguez-MínguezSara, Solís-García Del PozoJulián, JordánJoaquín

Improved motor symptoms
Parkinson's disease treatment
Prevention of motor complications

Rasagiline is a drug used to treat Parkinson's disease. In a review of studies, it was found to be effective in reducing Parkinson's disease symptoms. However, more studies are needed to determine the clinical significance of these findings.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.

Author: BaroneP, SantangeloG, MorganteL, OnofrjM, MecoG, AbbruzzeseG, BonuccelliU, CossuG, PezzoliG, StanzioneP, LopianoL, AntoniniA, TinazziM

Depressive symptoms
PD treatment

Rasagiline did not have significant effects on depressive symptoms or cognition in PD patients with moderate depressive symptoms.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Effects of rasagiline on Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson's disease: A post-hoc analysis of clinical trials in Japan.

Author: HattoriNobutaka, TakedaAtsushi, HanyaYuki, KitagawaTadayuki, AraiMasaki, FurusawaYoshihiko, MochizukiHideki, NagaiMasahiro, TakahashiRyosuke

HRQoL improvement

This study examined the impact of rasagiline, a medication for Parkinson's disease, on health-related quality of life (HRQoL). Japanese patients treated with rasagiline reported better HRQoL outcomes on the emotional well-being domain of the Parkinson's Disease Questionnaire (PDQ-39) compared to placebo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.

Author: HanagasiHasmet A, GurvitHakan, UnsalanPınar, HorozogluHilal, TuncerNese, FeyziogluAynur, GunalDilek Ince, YenerGorsev G, CakmurRaif, SahinHuseyin A, EmreMurat

Improved attention
Improved cognition

This randomized, double-blind, placebo-controlled study assessed the effects of rasagiline on cognitive deficits in cognitively impaired, non-demented Parkinson's disease patients. Rasagiline showed significant improvement in digit span-backward and verbal fluency scores compared to placebo, suggesting potential beneficial effects on attention and executive functions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases.

Author: LuanFeng, CordeiroM Natália D S, AlonsoNerea, García-MeraXerardo, CaamañoOlga, Romero-DuranFrancisco J, YañezMatilde, González-DíazHumberto

Neuroprotective drug discovery

This study developed the first mx-QSAR model for predicting neurotoxicity/neuroprotective effects of drugs based on multiplexing assays. This model showed high accuracy, sensitivity, and specificity in classifying neuroprotective compounds.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.

Author: GoggiJ, TheofilopoulosS, RiazS S, JauniauxE, SternG M, BradfordH F

dopaminergic survival
neuronal survival

Rasagiline, a monoamine oxidase B inhibitor, was shown to be more effective than deprenyl in protecting neurons from cell loss in vitro. Rasagiline increased the survival of both total neurons and dopaminergic neurons without increasing the survival of GABAergic neurons.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Author: SzökőÉva, TábiTamás, RiedererPeter, VécseiLászló, MagyarKálmán

Neuroprotection
Parkinson's treatment
MAO-B inhibition

MAO-B inhibitors, such as selegiline and rasagiline, have been used to treat Parkinson's disease for over 50 years. These drugs are generally well tolerated and do not cause the side effects associated with non-selective MAO inhibitors. In addition to their MAO-B inhibition activity, selegiline and rasagiline have also been shown to have neuroprotective and antiapoptotic properties.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Nephroprotective effects of TVP1022, a non-MAO inhibitor S-isomer of rasagiline, in an experimental model of diabetic renal ischemic injury.

Author: Abu-SalehNiroz, AwadHoda, KhamaisiMogher, ArmalyZaher, KarramTony, HeymanSamuel N, KaballaAviva, IchimuraTakaharu, HolmanJames, AbassiZaid

Improved renal function
Reduced histological changes

This study investigates the protective effects of TVP1022 and tempol on ischemic acute kidney injury (iAKI) in diabetic rats.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Rasagiline treatment effects on parkinsonian tremor.

Author: LewMark F

Reduced tremor severity

This review summarizes the effects of rasagiline on parkinsonian tremor. Two large placebo-controlled trials showed that rasagiline monotherapy significantly improved tremor symptoms in early Parkinson's disease (PD). Adding rasagiline to optimized dopaminergic therapy in levodopa-treated patients with motor fluctuations also significantly improved tremor symptoms.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.

Author: TazikShawna, JohnsonShakevia, LuDeyin, JohnsonChandra, YoudimMoussa B H, StockmeierCraig A, OuXiao-Ming

Neuroprotection

Rasagiline, an MAO B inhibitor, showed the highest neuroprotective effect against dexamethasone-induced brain cell death compared to selegiline and its metabolite, 1-R-aminoindan, suggesting its potential for treating stress-related depression.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.

Author: JennerPeter, LangstonJ William

neuroprotective
symptomatic benefit

Rasagiline, a drug used to treat Parkinson's disease (PD), may have disease-modifying effects by acting on mitochondria.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

13.

Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study.

Author: CibulcikFrantisek, BenetinJan, KurcaEgon, GrofikMilan, DvorakMiloslav, RichterDenis, DonathVladimir, KothajJan, MinarMichal, ValkovicPeter

Improved mobility
Improved quality of life
Reduced freezing of gait

This open-label study investigated the efficacy of rasagiline as add-on therapy for freezing of gait (FoG) in patients with Parkinson's disease. The study found that rasagiline significantly improved mobility, reduced FoG severity, and improved quality of life in patients with FoG.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

14.

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

Author: deMarcaidaJ Antonelle, SchwidSteven R, WhiteWilliam B, BlindauerKaren, FahnStanley, KieburtzKarl, SternMatthew, ShoulsonIra,

No tyramine interaction
Parkinson's treatment

Rasagiline, a selective MAO-B inhibitor for Parkinson's disease, did not cause clinically significant tyramine reactions in patients receiving 0.5 to 2 mg daily. Therefore, rasagiline can be used as monotherapy or adjunct to levodopa without dietary tyramine restrictions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.

Author: PoeweWerner, HauserRobert A, LangAnthony,

Less nM-EDL deterioration

Rasagiline 1 mg/day was associated with significantly less decline in nonmotor experiences of daily living compared to placebo in early Parkinson's disease (PD) patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Possible neuroprotective effects of rasagiline in Alzheimer's disease: a SPECT study.

Author: SongIn-Uk, ImJooyeon Jamie, JeongHyeonseok, NaSeung-Hee, ChungYong-An

Potential AD treatment

This study aims to elucidate the effects of rasagiline on the brains of patients with Alzheimer's disease (AD). While rasagiline has shown beneficial effects in other neurodegenerative diseases, its impact on AD remains unclear.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Effects of rasagiline on olfactory function in patients with Parkinson’s disease.

Author: HaehnerAntje, HummelThomas, WolzMartin, KlingelhöferLisa, FauserMareike, StorchAlexander, ReichmannHeinz

No effect on olfaction

A randomized controlled trial of 34 patients with Parkinson’s disease found no significant difference in olfactory function between patients treated with rasagiline, a MAO-B inhibitor, and those treated with placebo. The study did not reach the primary endpoint and therefore could not demonstrate a specific effect of rasagiline on olfaction in PD patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia.

Author: MatthewsDawn C, RitterAaron, ThomasRonald G, AndrewsRandolph D, LukicAna S, RevtaCarolyn, KinneyJefferson W, TousiBabak, LeverenzJames B, FillitHoward, ZhongKate, FeldmanHoward H, CummingsJeffrey

Improved regional brain metabolism

This Phase II trial evaluated the effects of rasagiline, a monoamine oxidase B inhibitor, in patients with mild to moderate Alzheimer's disease. The study found that rasagiline did not improve regional brain metabolism compared to placebo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.